Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by vascular endothelial growth factor-mediated enhancer of zeste homolog-2/vasohibin 1 pathway and may be a potentially useful therapeutic target for hepatocellular carcinoma.
|
31757187 |
2020 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There was a moderately significant correlation between vascular endothelial growth factor levels and hepatocellular carcinoma stage (ρ = 0.464, P = 0.001).
|
31790004 |
2020 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the immunohistochemical expression of vascular endothelial growth factor (VEGF) and angiopoietin-2 in HCC and precursors lesion in a single institution series of whole liver explants between 2013 and 2015, evaluating morphologic and clinical variables.
|
27556821 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of alpha-fetoprotein, des-γ-carboxy prothrombin, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (alpha-fetoprotein-L3%), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, as well as the plasma levels of von Willebrand factor antigen (von Willebrand factor: Ag) and ADAMTS13 activity (ADAMTS13:AC), were evaluated in 41 cirrhotic patients with HCC undergoing radiofrequency ablation and in 20 cirrhotic patients without HCC.
|
31638892 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations between polymorphisms in vitamin D receptor (VDR)/vascular endothelial growth factor (VEGF)/interleukin-18 (IL-18)/mannose-binding lectin (MBL) and susceptibility to hepatocellular carcinoma (HCC) were already explored by many studies, yet the results of these studies were inconsistent.
|
31830994 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These VEGF-enriched exosomes significantly promoted the formation of endothelial vessels and vasculogenic mimicry in hepatocellular carcinoma and its progression in mice.
|
31258881 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, in vitro inhibiting hepatocellular carcinoma of the pH-sensitive sorafenib (Sf) and VEGF-siRNA co-loaded liposomes was discussed.
|
30977418 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sorafenib, a multi-kinase VEGF inhibitor, is the most widely used systemic chemotherapy approved as a first-line agent for unresectable or advanced HCC.
|
30600478 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, there was a significant association of the expressions of Ihh and VEGF proteins in HCC (r=0.6, P<0.0001), and of Ihh and CD34 staining (r=0.261, P=0.012).
|
29629949 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patient-derived xenograft (PDX) mice model was established to investigate the effect of VEGF pathway in incomplete RFA of HCC with high fidelity.
|
31173855 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, BBP treatment remarkably suppressed the STAT3 phosphorylation and modulated the expression of critical target genes including Bcl-2, Bax, Cyclin D1, CDK4 and VEGF-A in HCC mice.
|
30810974 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One-year mPFS was statistically longer in LCC (46.8% vs. 24.2%, p=0.0005). mPFS was longer in LCC treated with anti-VEGF vs. anti-EGFR (p=0.06).
|
31519596 |
2019 |
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, our results demonstrated that LINC00628 could function as a tumor suppressor in HCC via its conserved sequence elements interacting with a particular region of VEGFA promoter, suggesting that LINC00628 may serve as a novel promising target for diagnosis and therapy in HCC.
|
30740671 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
STAT3 activated by LPS increases the production of vascular endothelial growth factor (VEGF) by tumor cells, which not only promotes the proliferation of HCC cells but also stimulates the migration and tubulogenesis of endothelial cells through STAT3 activation and hence promotes angiogenesis in HCC.
|
30521872 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further studies revealed that RP11-564D11.3 functions as a competitive endogenous RNA through targeting VEGFA in hepatocellular carcinoma.
|
30362374 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, our study demonstrated that RUNX1 functions as a repressor in the HCC and this suppressive function was dependent on its effect on VEGFA.
|
31289995 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At weeks 12 and 16 post-induction, effects were compared on HCC nodule formation, microvessel density, and macrophage infiltration, and levels of paraneoplastic protein expression of tumor necrosis factor (TNF)-α, p38 mitogen-activated protein kinase (p38), phosphorylated p38 (p-p38), nuclear factor (NF)-κB, interleukin (IL)-10, hepatocyte growth factor (HGF), transforming growth factor (TGF)-β1 and vascular endothelial growth factor (VEGF).
|
31807025 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further engineered MSCs to express the sodium iodide symporter (<i>NIS</i>) reporter gene under control of a hypoxia-responsive promoter and the vascular endothelial growth factor (VEGF) promoter to test effects on these pathways <i>in vitro</i> and, for VEGF, <i>in vivo</i> in an orthotopic hepatocellular carcinoma (HCC) xenograft mouse model by positron emission tomography imaging.
|
31816265 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The obtained data revealed that administration of Mel before MSCs treatment without preconditioning yielded a better ameliorative effect against DEN-induced hepatocellular carcinoma (HCC) as evidenced by: 1) reduced serum levels of alpha fetoprotein and gamma-glutamyl transferase; 2) decreased number and area of glutathione S-transferase placental positive foci; 3) induced apoptosis (as indicated by increased cleaved caspase-3 activity, upregulated expression of proapoptotic genes Bax and caspase 3 and downregulated expression of anti-apoptotic genes Bcl2, survivin); 4) decreased malondialdehyde level and increased activities of superoxide dismutase, catalase, and glutathione peroxidase enzymes; and 5) reduced inflammation, angiogenesis and metastasis as indicated by downregulated expression of interleukin 1 beta, nuclear factor kappa B, vascular endothelial growth factor, and matrix metallopeptidase 9 genes and upregulated expression of metalloproteinase inhibitor 1 gene.
|
30925457 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum AREG and VEGF levels were assayed by ELISA in 55 patients with advanced HCC treated with sorafenib.
|
30569112 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In VEGF-overexpressing HCC xenograft models, characterized by aggressive tumor growth and hypervascularity, lenvatinib had significant antitumor and antiangiogenic activities.
|
31006280 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that YY1 plays essential roles in HCC angiogenesis and resistance of bevacizumab by inducing VEGFA transcription and that YY1 may represent a potential molecular target for antiangiogenic therapy during HCC progression.
|
31799179 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC.
|
30879152 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lenvatinib (an inhibitor of vascular endothelial growth factor (GF) receptors 1-3, fibroblast GF receptors 1-4, platelet-derived GF receptor α, rearranged during transfection, and stem cell factor receptor) was non-inferior to sorafenib in a phase 3 (REFLECT) trial of advanced hepatocellular carcinoma.
|
30671808 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The woodchuck is a well-characterized model of hepatitis B virus related HCC and a valuable tool for translational studies of novel VEGF targeted agents.
|
30439360 |
2019 |